Reviewing ZIOPHARM Oncology (NASDAQ:ZIOP) and The Competition

ZIOPHARM Oncology (NASDAQ: ZIOP) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare ZIOPHARM Oncology to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk.

Insider & Institutional Ownership

40.2% of ZIOPHARM Oncology shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.4% of ZIOPHARM Oncology shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ZIOPHARM Oncology and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIOPHARM Oncology 0 1 2 0 2.67
ZIOPHARM Oncology Competitors 1134 3426 11925 240 2.67

ZIOPHARM Oncology currently has a consensus target price of $16.50, suggesting a potential upside of 278.44%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.51%. Given ZIOPHARM Oncology’s higher possible upside, equities analysts plainly believe ZIOPHARM Oncology is more favorable than its rivals.

Volatility and Risk

ZIOPHARM Oncology has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, ZIOPHARM Oncology’s rivals have a beta of 0.79, suggesting that their average stock price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares ZIOPHARM Oncology and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ZIOPHARM Oncology $6.86 million -$165.29 million -8.38
ZIOPHARM Oncology Competitors $290.27 million $35.99 million 59.68

ZIOPHARM Oncology’s rivals have higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares ZIOPHARM Oncology and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ZIOPHARM Oncology -818.19% N/A -47.07%
ZIOPHARM Oncology Competitors -5,441.68% -162.70% -35.92%


ZIOPHARM Oncology rivals beat ZIOPHARM Oncology on 9 of the 13 factors compared.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with's FREE daily email newsletter.

Leave a Reply